In the BioHarmony Drug Report Database

"Preview" Icon

Fluciclovine (18f)

Axumin (fluciclovine f18) is a small molecule pharmaceutical. Fluciclovine f18 was first approved as Axumin on 2016-05-27. It has been approved in Europe to treat prostatic neoplasms and radionuclide imaging. Axumin’s patents are valid until 2035-12-30 (FDA).

 

Trade Name

 

Axumin
 

Common Name

 

fluciclovine f18
 

ChEMBL ID

 

CHEMBL3707267
 

Indication

 

prostatic neoplasms, radionuclide imaging
 

Drug Class

 

Vinca alkaloids

Image (chem structure or protein)

Fluciclovine (18f) structure rendering